{"groups":[{"description":"Brentuximab vedotin 1.8 mg/kg every 3 weeks by intravenous (IV) infusion","id":"FG000","title":"Brentuximab Vedotin"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"13"}],"type":"Progressive disease"},{"reasons":[{"groupId":"FG000","numSubjects":"16"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"14"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"5"}],"type":"Withdrawal by Subject"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"58"}],"type":"STARTED"},{"achievements":[{"comment":"Number who completed 16 cycles of treatment","groupId":"FG000","numSubjects":"10"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"48"}],"type":"NOT COMPLETED"}],"title":"Treatment Period"},{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"5"}],"type":"Lost to Follow-up"}],"milestones":[{"achievements":[{"comment":"All participants were to be followed after treatment","groupId":"FG000","numSubjects":"58"}],"type":"STARTED"},{"achievements":[{"comment":"Completed survival follow-up due to death \\[25\\] or study completion \\[28\\]","groupId":"FG000","numSubjects":"53"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"5"}],"type":"NOT COMPLETED"}],"title":"Follow-up Period"}],"recruitmentDetails":"Enrollment period: Jun 2009 - May 2010"}